Indivior obtained top-line results from its phase III clinical trial of RBP-7000, a candidate treatment for schizophrenia. Based on these successful outcomes, the company expects to submit a New Drug Application to the U.S. FDA for potential approval in 2017.

Schizophrenia is a chronic, severe and disabling brain disorder that affects an estimated 26 million people worldwide. Indivior’s treatment aims at reducing or eliminating the symptoms of the disease.

“With these positive phase 3 data in hand, we are moving forward expeditiously to complete the open-label long-term assessment of the safety and tolerability of RBP-7000” said Christian Heidbreder, Ph.D., Chief Scientific Officer of Indivior.

The stockmarket is also reacting to these hopeful results, as the English biotech showed an increase in its valuation since the announcement.

Previous post

GSK sparks off the Gene Therapy resurgence

Next post

Are AbbVie and J&J already fighting to acquire Galapagos' pipeline?

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.